A pharmacometric grey zone reconciles high metronidazole resistance rates with bismuth quadruple therapy efficacy in Helicobacter pylori
He, C.; Wang, H.; Xu, X.
Show abstract
Summary Background Metronidazole (MET) resistance in Helicobacter pylori (H. pylori) exceeds 50-60% globally, yet MET-containing bismuth quadruple therapy (BQT) achieves >90% eradication in MET-resistant infections. We hypothesise this discordance stems from a structural limitation of two-fold dilution: a pharmacometric grey zone between the 128 and 256 µg/mL breakpoints where treatable isolates are systematically misclassified as high-level resistance. Methods In a real-world cohort of 4610 treatment-naïve children (2019-2024), checkerboard assays determined the bismuth-MET synergy factor (SF). Population PK/PD modelling simulated gastric MET exposure (AUC<sub>0-24</sub>/MIC &ge 70) at 1 g, 1·5 g and 2 g daily doses, incorporated bismuth SF, and estimated MIC coverage against the European Committee on Antimicrobial Susceptibility Testing (EUCAST) population distribution. Findings were validated against published adult trials. Findings 56·4% (485/860) of isolates were MET-resistant (MIC > 8 µg/mL). At [≤] 1 g/day MET, BQT offered no advantage over triple therapy for resistant infections. At 1·5 g/day, the synergy threshold was surpassed, achieving >90% eradication in MET-resistant infections, with efficacy independent of baseline susceptibility status. PK/PD modelling showed 1·5 g/day MET plus bismuth (median SF = 8) extended coverage to ~180 µg/mL. To align modelled coverage with the >90% eradication rate, the dominant subpopulation of nominally high-resistant isolates must have a geometric mean MIC well below 256 µg/mL (centred near 150 µg/mL), consistent with a mixture of two log-normal subpopulations and confirming systematic upward misclassification by two-fold dilution in the grey zone. Interpretation This grey zone is a structural blind spot of two-fold dilution, not random measurement error. The ±1-dilution reproducibility limit renders the interval inherently unresolvable. We propose a three-tier strategy: omit routine MET susceptibility testing for treatment-naïve patients on optimised BQT; reserve categorical testing for BQT failures; and explore genomic/metabolomic biomarkers beyond MIC paradigms in this enriched population. Funding None. Keywords: Helicobacter pylori; Metronidazole resistance; Bismuth quadruple therapy; Antimicrobial susceptibility testing; Pharmacokinetic/pharmacodynamic modelling; Pharmacometric grey zone
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Machine Learning-Based Prediction of Pediatric Ulcerative Colitis Treatment Response using Diagnostic Histopathology 89%
- Prolonged Antibiotic Treatment Generates a Fluoroquinolone Resistant Gut Microbiome and Collateral Multi-Drug Resistance 88%
- Tofacitinib uptake by patient-derived intestinal organoids predicts individual clinical responsiveness 88%
Similar papers in this journal
- Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach 91%
- Effect of biannual azithromycin distribution on antibody responses to malaria, bacterial, and protozoan pathogens among children: A cluster-randomized, placebo-controlled trial in Niger 91%
- Allergic to Confounding: Leveraging Penicillin Allergy as an Instrumental Variable to Estimate the Causal Effect of Antibiotic Use on Resistance 91%
Similar papers in this journal
- Ex vivo susceptibility to antimalarial drugs and polymorphisms in drug resistance genes of African Plasmodium falciparum , 2016-2023: a genotype-phenotype association study 91%
- Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics 90%
- Characterising heterogeneity and sero-reversion in antibody responses to mild SARS⍰CoV-2 infection: a cohort study using time series analysis and mechanistic modelling 89%
Similar papers in this journal
- DrugWAS: Leveraging drug-wide association studies to facilitate drug repurposing for COVID-19 90%
- Innovative Randomized Phase 1 Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir 90%
- Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics 89%
Similar papers in this journal
- People exposed to proton pump inhibitors shortly preceding COVID-19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: a nation-wide matched cohort study 92%
- Population Pharmacokinetic Analysis of Dexmedetomidine in Children using Real-World-Data Obtained from Electronic Health Records and Remnant Clinic Samples 88%
- Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals 88%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.